Biogen has initiated the BRAVE study, a global Phase 3 clinical trial to evaluate omaveloxolone in children with Friedreich ataxia, addressing a critical unmet need in the pediatric population.

Roche is moving its novel antibiotic zosurabalpin into phase 3 testing for carbapenem-resistant Acinetobacter baumannii (CRAB), a 'superbug' that is considered an 'urgent threat' by the CDC, in ...

Guardians Guardians approach a tipping point with three straight series against division leaders Published: Jun. 30, 2025, 2:00 p.m.